Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 5, Issue 1
  5. Article
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Risk stratification in pulmonary arterial hypertension is critical in determining therapeutic strategies for patients. Patients are stratified into low-, intermediate-, and high-risk groups based on determinants of prognosis like clinical assessment, exercise tests, biochemical markers, echocardiography, and haemodynamic tests. The primary objective of treatment is to shift each of the component tests into a low-risk zone either by treatment escalation alone, as in the case of intermediate-risk patients, or by a combination of treatment escalation and repeat evaluation by right heart catheterisation in high-risk patients. Low-risk patients should be clinically assessed at least every 3 months, but follow-up is more frequent for intermediate- and high-risk patients. Apart from improving survival rates, health-related quality of life is also assessed at baseline and follow-up visits, which may predict the prognosis. Additionally, therapeutic drug monitoring is also essential during visits due to the risk of major side effects during treatment initiation or dose escalation. Initial and follow-up risk stratification can prevent delays in the intensification of therapy, but insurance denials act as a barrier to this approach. Therefore, a dedicated insurance team is required for approval of testing and therapies and a fast-track process to communicate with the pulmonary hypertension expert centre. It can be concluded that risk stratification improves the treatment approach and helps make individualised treatment decisions. It also helps healthcare professionals better allocate treatment resources in cases of scarcity.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882333499241114120006
2024-01-01
2025-04-25

  • From This Site

    /content/journals/nemj/10.2174/0102506882333499241114120006
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. HumbertM KovacsG HoeperMM BadagliaccaR BergerRMF BridaM ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.Eur Respir J.20236112200879
     [Google Scholar]
  2. ZelnikerT. UhlmannL. SpaichS. FriedrichJ. PreuschM.R. MeyerF.J. KatusH.A. GiannitsisE. Novel biomarkers for risk stratification in pulmonary arterial hypertension.ERJ Open Res.20151200008-201510.1183/23120541.00008‑201527730146
     [Google Scholar]
  3. GalièN. ChannickR.N. FrantzR.P. GrünigE. JingZ.C. MoiseevaO. PrestonI.R. PulidoT. SafdarZ. TamuraY. McLaughlinV.V. Risk stratification and medical therapy of pulmonary arterial hypertension.Eur. Respir. J.2019531180188910.1183/13993003.01889‑201830545971
     [Google Scholar]
  4. van de VeerdonkM.C. KindT. MarcusJ.T. MauritzG.J. HeymansM.W. BogaardH.J. BoonstraA. MarquesK.M.J. WesterhofN. Vonk-NoordegraafA. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.J. Am. Coll. Cardiol.201158242511251910.1016/j.jacc.2011.06.06822133851
     [Google Scholar]
  5. van WolferenS.A. MarcusJ.T. BoonstraA. MarquesK.M.J. BronzwaerJ.G.F. SpreeuwenbergM.D. PostmusP.E. Vonk-NoordegraafA. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension.Eur. Heart J.200728101250125710.1093/eurheartj/ehl47717242010
     [Google Scholar]
  6. van de VeerdonkM.C. MarcusJ.T. WesterhofN. de ManF.S. BoonstraA. HeymansM.W. BogaardH.J. Vonk NoordegraafA. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension.Chest201514741063107110.1378/chest.14‑070125376008
     [Google Scholar]
  7. SwiftA.J. RajaramS. CampbellM.J. HurdmanJ. ThomasS. CapenerD. ElliotC. CondliffeR. WildJ.M. KielyD.G. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension.Circ. Cardiovasc. Imaging20147110010610.1161/CIRCIMAGING.113.00033824275955
     [Google Scholar]
  8. HumbertM. LauE.M.T. Risk stratification in pulmonary arterial hypertension: Do not forget the patient perspective.Am. J. Respir. Crit. Care Med.2021203667567710.1164/rccm.202012‑4350ED33357026
     [Google Scholar]
  9. WeatheraldJ. BouclyA. SitbonO. Risk stratification in pulmonary arterial hypertension.Curr. Opin. Pulm. Med.201824540741510.1097/MCP.000000000000051030004992
     [Google Scholar]
  10. HoeperM.M. PletzM.W. GolponH. WelteT. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension.Eur. Respir. J.200729594495010.1183/09031936.0013450617301100
     [Google Scholar]
  11. MinJ. BadeschD. ChakinalaM. ElwingJ. FrantzR. HornE. KlingerJ. LammiM. MazimbaS. SagerJ. ShlobinO. SimonM. ThenappanT. GrinnanD. VentetuoloC. Al-NaamaniN. RavalA. RainaA. HemnesA. BurgerC. Dunbar IvyD. YungD. ZwickeD. Berman-RosenzweigE. RamaniG. FarrG. James FordH. RunoJ. FinemanJ. FeldmanJ. SwisherJ. RyanJ. Wesley McConnellJ. PresbergK. ParikhK. CadaretL. AvdalovicM. DuncanM. EggertM. VargheseN. BoyceP. LearyP. FoleyR. James WhiteR. FrantzR. ZamanianR. HirschR. BakshiS. BartolomeS. KawutS. MathaiS. De MarcoT. WilliamsonT. BullT. PHAR Investigators Prediction of health-related quality of life and hospitalization in pulmonary arterial hypertension: The pulmonary hypertension association registry.Am. J. Respir. Crit. Care Med.2021203676176410.1164/rccm.202010‑3967LE33211974
     [Google Scholar]
  12. BouclyA. WeatheraldJ. SavaleL. JaïsX. CottinV. PrevotG. PicardF. de GrooteP. JevnikarM. BergotE. ChaouatA. ChabanneC. BourdinA. ParentF. MontaniD. SimonneauG. HumbertM. SitbonO. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.Eur. Respir. J.2017502170088910.1183/13993003.00889‑201728775050
     [Google Scholar]
  13. ZelnikerT.A. HuscherD. Vonk-NoordegraafA. EwertR. LangeT.J. KloseH. DumitrescuD. HalankM. HeldM. GallH. PittrowD. HoeperM.M. FrankensteinL. The 6MWT as a prognostic tool in pulmonary arterial hypertension: Results from the COMPERA registry.Clin. Res. Cardiol.2018107646047010.1007/s00392‑018‑1207‑529368137
     [Google Scholar]
  14. SitbonO. BenzaR.L. BadeschD.B. BarstR.J. ElliottC.G. GressinV. LemariéJ.C. MillerD.P. Muros-Le RouzicE. SimonneauG. FrostA.E. FarberH.W. HumbertM. McGoonM.D. Validation of two predictive models for survival in pulmonary arterial hypertension.Eur. Respir. J.201546115216410.1183/09031936.0000441425837032
     [Google Scholar]
  15. GalièN. HumbertM. VachieryJ.L. GibbsS. LangI. TorbickiA. SimonneauG. PeacockA. Vonk NoordegraafA. BeghettiM. GhofraniA. Gomez SanchezM.A. HansmannG. KlepetkoW. LancellottiP. MatucciM. McDonaghT. PierardL.A. TrindadeP.T. ZompatoriM. HoeperM. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur. Respir. J.201546490397510.1183/13993003.01032‑201526318161
     [Google Scholar]
  16. GalièN. HumbertM. VachieryJ.L. GibbsS. LangI. TorbickiA. SimonneauG. PeacockA. Vonk NoordegraafA. BeghettiM. GhofraniA. Gomez SanchezM.A. HansmannG. KlepetkoW. LancellottiP. MatucciM. McDonaghT. PierardL.A. TrindadeP.T. ZompatoriM. HoeperM. ESC Scientific Document Group ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.Eur. Heart J.20163716711910.1093/eurheartj/ehv31726320113
     [Google Scholar]
  17. DiamantiE. KaravaV. YerlyP. AubertJ.D. Carbon monoxide diffusion capacity as a severity marker in pulmonary hypertension.J. Clin. Med.202111113210.3390/jcm1101013235011871
     [Google Scholar]
  18. BenzaR.L. KanwarM.K. RainaA. ScottJ.V. ZhaoC.L. SelejM. ElliottC.G. FarberH.W. Development and Validation of an abridged version of the reveal 2.0 risk score calculator, reveal lite 2, for use in patients with pulmonary arterial hypertension.Chest2021159133734610.1016/j.chest.2020.08.206932882243
     [Google Scholar]
  19. FrantzRP SO RainaA WuB BroderickM Change in reveal lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: A retrospective chart review.Eur. Heart J.2022432544.1919
     [Google Scholar]
  20. BouclyA. WeatheraldJ. SavaleL. de GrooteP. CottinV. PrévotG. ChaouatA. PicardF. Horeau-LanglardD. BourdinA. JutantE.M. BeurnierA. JevnikarM. JaïsX. SimonneauG. MontaniD. SitbonO. HumbertM. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.Eur. Respir. J.2022596210241910.1183/13993003.02419‑202134737227
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882333499241114120006
Loading
Risk Stratification in Pulmonary Hypertension in the UAE
NEW Emirates Medical J 5, e02506882333499 (2024); https://doi.org/10.2174/0102506882333499241114120006
/content/journals/nemj/10.2174/0102506882333499241114120006
/content/journals/nemj/10.2174/0102506882333499241114120006
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Biochemical markers; Exercise capacity; Pulmonary arterial hypertension; Right ventricular function; Risk stratification; Treatment response

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test